keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#1
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
April 20, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28422773/infections-in-rheumatoid-arthritis
#2
Fabiola Atzeni, Ignazio Francesco Masala, Manuela di Franco, Piercarlo Sarzi-Puttini
PURPOSE OF REVIEW: The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months. RECENT FINDINGS: New studies have further strengthened existing evidence relating the use of biological drugs to serious infections...
April 18, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28420837/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-with-six-months-of-biological-dmards-treatment
#3
Yusuke Miwa, Ryo Takahashi, Yuzo Ikari, Airi Maeoka, Shinichiro Nishimi, Nao Oguro, Tomoki Hayashi, Mika Hatano, Sakiko Isojima, Ryo Yanai, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki, Kenji Sanada
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28415924/an-assessment-of-the-current-treatment-landscape-for-rheumatology-patients-in-qatar-recognising-unmet-needs-and-moving-towards-solutions
#4
Samar Al Emadi, Mohammed Hammoudeh, Mohamed Mounir, Ruediger B Mueller, Alvin F Wells, Housam Aldeen Sarakbi
Objective This study assessed the mode of application (oral, intravenous or subcutaneous (SC)) currently employed in the treatment of rheumatoid arthritis (RA) in patients from Qatar in comparison with patients' individual preferences for the mode of application of their treatment. Methods This study included 294 RA patients visiting three clinics at the main referral hospital in Qatar who were interviewed using a standard questionnaire to determine their preference of mode of application for their disease-modifying antirheumatic drug (DMARD) treatment in relation to their currently employed mode of application...
April 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28412711/biologic-disease-modifying-antirheumatic-drug-bdmard-induced-neutropenia-a-registry-from-a-retrospective-cohort-of-patients-with-rheumatic-diseases-treated-with-3-classes-of-intravenous-bdmard
#5
Francisco Espinoza, Pierre Le Blay, Bernard Combe
OBJECTIVE: To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD). METHODS: We conducted a retrospective cohort study in 499 patients with rheumatic diseases treated by IV abatacept (ABA), infliximab (IFX), or tocilizumab (TCZ). RESULTS: Rheumatoid arthritis (RA) was the most frequent diagnosis (72%). Fifty-two patients (10.4%) experienced at least 1 episode of neutropenia...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28412710/triple-oral-therapy-versus-antitumor-necrosis-factor-plus-methotrexate-mtx-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-mtx-a-systematic-literature-review
#6
Julia Mary, Michel De Bandt, Cédric Lukas, Jacques Morel, Bernard Combe
OBJECTIVE: For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28412701/association-between-medications-and-herpes-zoster-in-japanese-patients-with-rheumatoid-arthritis-a-5-year-prospective-cohort-study
#7
Sayoko Harada, Ryoko Sakai, Fumio Hirano, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: To investigate the association between medications and herpes zoster (HZ) in patients with rheumatoid arthritis (RA) given biological disease-modifying antirheumatic drugs (bDMARD) or conventional synthetic DMARD in the clinical setting during 5 years using the Registry of Japanese Rheumatoid Arthritis Patients on Biologics for Longterm Safety (REAL) database. METHODS: We calculated the crude incidence rate (IR) of HZ treated with systemic antiviral medications in 1987 patients from the REAL database...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28408930/a-case-of-initially-undiagnosed-chikungunya-arthritis-developing-into-chronic-phase-in-a-nonendemic-area
#8
Pui Shan Julia Chan, Moon Ho Leung
This case report described a 40-year-old lady presented with fever, headache, arthralgia, myalgia, and impaired liver function after returning from the Philippines. Chikungunya virus (CHIKV) and dengue serology were negative. Eight weeks after initial presentation, she experienced inflammatory polyarthritis mimic rheumatoid arthritis. This time CHIKV-IgM was detected, together with a >4-fold rise of CHIKV-polyvalent-antibody titre. The first CHIKV-IgM negative sample was reexamined and was CHIKV-PCR positive...
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#9
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28405755/-sarcoidosis-renal-manifestations
#10
REVIEW
C Löffler, R Bergner
Renal involvement in sarcoidosis is much more common than generally assumed from old epidemiological studies and is often only detected when actively searched for. Many patients with renal sarcoidosis present with no or only few symptoms. The diagnostic work-up of sarcoidosis should always include a possible renal involvement. In cases of impaired renal function, proteinuria or a pathological urine sediment, a renal biopsy specimen should be obtained to assess the type, severity and prognosis of the kidney disease...
April 12, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28405473/patient-reported-outcomes-from-a-phase-iii-study-of-baricitinib-in-patients-with-conventional-synthetic-dmard-refractory-rheumatoid-arthritis
#11
Paul Emery, Ricardo Blanco, Jose Maldonado Cocco, Ying-Chou Chen, Carol L Gaich, Amy M DeLozier, Stephanie de Bono, Jiajun Liu, Terence Rooney, Cecile Hsiao-Chun Chang, Maxime Dougados
OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227). PROs included the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, measures from patient electronic daily diaries (duration and severity of morning joint stiffness (MJS), Worst Tiredness, Worst Joint Pain), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores and visual analogue scales (VAS) and the Work Productivity and Activity Impairment Questionnaire-RA...
2017: RMD Open
https://www.readbyqxmd.com/read/28399940/baseline-jak-phosphorylation-profile-of-peripheral-blood-leukocytes-studied-by-whole-blood-phosphospecific-flow-cytometry-is-associated-with-1-year-treatment-response-in-early-rheumatoid-arthritis
#12
Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Hannu Kautiainen, Heikki Repo, Marjatta Leirisalo-Repo
BACKGROUND: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in peripheral blood CD4(+) T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA. METHODS: Thirty-five DMARD-naïve patients with early RA provided blood samples for whole blood flow cytometric determination of phosphorylation of JAKs in CD4(+) and CD8(+) T cells, CD19(+) B cells, and CD14(+) monocytes...
April 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28386136/assessment-of-anti-carp-antibodies-disease-activity-and-quality-of-life-in-rheumatoid-arthritis-patients-on-conventional-and-biological-disease-modifying-antirheumatic-drugs
#13
Sudhir Kumar, Ghanshyam Pangtey, Rachna Gupta, Harmeet Singh Rehan, Lalit Kumar Gupta
OBJECTIVE: Good biomarkers are important to guide decisions in the clinical management of rheumatoid arthritis (RA). RA patients harbor antibodies directed against carbamylated proteins which may predict joint damage. This study investigated whether antibodies against carbamylated proteins (anti-CarP) may serve as surrogate prognostic markers. MATERIAL AND METHODS: Fifty-three patients with a diagnosis of rheumatoid arthritis according to ACR 1987 criteria were included...
2017: Reumatologia
https://www.readbyqxmd.com/read/28377787/tofacitinib-versus-biologic-treatments-in-moderate-to-severe-rheumatoid-arthritis-patients-who-have-had-an-inadequate-response-to-nonbiologic-dmards-systematic-literature-review-and-network-meta-analysis
#14
REVIEW
Evelien Bergrath, Robert A Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARDs (bDMARDs) and other novel DMARDs for second-line moderate-to-severe rheumatoid arthritis (RA) patients by means of a systematic literature review (SLR) and network meta-analysis (NMA). Methods. MEDLINE®, EMBASE®, and Cochrane Central Register of Controlled Trials were searched to identify randomized clinical trials (RCTs) published between 1990 and March 2015...
2017: International Journal of Rheumatology
https://www.readbyqxmd.com/read/28376912/head-to-head-comparison-of-aggressive-conventional-therapy-and-three-biological-treatments-and-comparison-of-two-de-escalation-strategies-in-patients-who-respond-to-treatment-study-protocol-for-a-multicenter-randomized-open-label-blinded-assessor-phase-4-study
#15
Daniel Glinatsi, Marte S Heiberg, Anna Rudin, Dan Nordström, Espen A Haavardsholm, Bjorn Gudbjornsson, Mikkel Østergaard, Till Uhlig, Gerdur Grondal, Kim Hørslev-Petersen, Ronald van Vollenhoven, Merete L Hetland
BACKGROUND: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two de-escalation strategies in patients who respond to first-line therapy...
April 4, 2017: Trials
https://www.readbyqxmd.com/read/28376239/clinical-characteristics-disease-activity-and-patient-reported-outcomes-in-psoriatic-arthritis-patients-with-dactylitis-or-enthesitis-results-from-the-corrona-psoriatic-arthritis-spondyloarthritis-registry
#16
Philip J Mease, Chitra Karki, Jacqueline B Palmer, Carol J Etzel, Arthur Kavanaugh, Christopher T Ritchlin, Wendi Malley, Vivian Herrera, Melody Tran, Jeffrey D Greenberg
OBJECTIVE: Characterize psoriatic arthritis (PsA) patients with dactylitis or enthesitis and evaluate the associations of these manifestations with disease activity and patient-reported outcomes. METHODS: Using the Corrona PsA/Spondyloarthritis Registry, patient characteristics, disease activity, and patient-reported outcomes at registry enrollment were assessed for PsA patients aged ≥ 18 years with or without dactylitis or enthesitis. Regression models were used to evaluate associations of dactylitis and enthesitis with outcomes including Minimal Disease Activity, Health Assessment Questionnaire scores, patient-reported pain and fatigue, and work productivity (Work Productivity and Activity Impairment questionnaire)...
April 4, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28375195/risk-factors-for-late-deep-infection-after-total-hip-arthroplasty-in-patients-with-rheumatoid-arthritis
#17
Shinya Hayashi, Shingo Hashimoto, Koji Takayama, Tomoyuki Matsumoto, Ken Takebe, Yasuhiro Terashima, Ryosuke Kuroda, Yoshitada Sakai, Kazunari Ishida, Kotaro Nishida
OBJECTIVE: Postoperative infections, a serious complication of orthopedic surgery, occur 2-4 times more frequently in patients with rheumatoid arthritis (RA) without adjustment for medication. Some studies have demonstrated a similar risk of postoperative infection following orthopedic surgery regardless of whether patients underwent tumor necrosis factor-α (TNF-α) inhibitor therapy; however, other studies have reported a higher risk with TNF-α inhibitor use. However, few reports have focused on the correlation between TNF-α inhibitor use and postoperative late infection...
January 21, 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28367079/reviewing-primary-sj%C3%A3-gren-s-syndrome-beyond-the-dryness-from-pathophysiology-to-diagnosis-and-treatment
#18
REVIEW
Tim Both, Virgil A S H Dalm, P Martin van Hagen, Paul L A van Daele
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease, characterized by lymphocytic infiltration of the secretory glands. This process leads to sicca syndrome, which is the combination of dryness of the eyes, oral cavity, pharynx, larynx and/or vagina. Extraglandular manifestations may also be prevalent in patients with pSS, including cutaneous, musculoskeletal, pulmonary, renal, hematological and neurological involvement. The pathogenesis of pSS is currently not well understood, but increased activation of B cells followed by immune complex formation and autoantibody production are thought to play important roles...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28364381/adalimumab-with-methotrexate-in-treatment-na%C3%A3-ve-japanese-patients-with-rheumatoid-arthritis-at-risk-of-progressive-structural-joint-damage-a-postmarketing-observational-study
#19
Yukiko Ito, Kaori Hozumi, Yukiko Okada, Sarina Kurimoto
INTRODUCTION: The objective of this study was to evaluate the real-world safety and effectiveness of adalimumab with methotrexate (MTX) in disease-modifying antirheumatic drug (DMARD)- and biologic-naïve Japanese patients with rheumatoid arthritis (RA) at risk of progressive structural joint damage. METHODS: This multicenter, prospective, observational, postmarketing surveillance study was conducted between February 2013 and April 2015 at 84 centers in Japan. Patients with RA at risk of progressive structural joint damage were enrolled and initiated treatment with adalimumab and MTX...
March 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28364136/relapsing-polychondritis-a-chameleon-among-orphan-diseases
#20
REVIEW
Sabine Schumacher, Herwig Pieringer
Relapsing polychondritis (RPC) is a rare disease with recurrent episodes of inflammation of cartilage tissue leading to fibrosis and organ damage. Despite unknown etiology, there is some evidence of a genetic predisposition. The clinical presentation is heterogeneous and an association with other autoimmune disorders such as rheumatoid arthritis or different forms of vasculitis has been described. All organ systems containing cartilage can be affected, such as ear, nose, joints, trachea, aorta, and coronary arteries...
March 31, 2017: Wiener Medizinische Wochenschrift
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"